We recently published our article 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. In this piece, we take a closer look at Altimmune Inc. (NASDAQ:ALT) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Novo Nordisk A/S (NYSE: NVO) helped transform obesity treatment from a relatively overlooked pharmaceutical category into one of Wall Street’s biggest healthcare stories. The success of GLP-1 weight-loss drugs proved that effective obesity medicines could generate blockbuster sales, attract millions of patients and reshape how doctors treat metabolic disease.
The opportunity is enormous. Obesity affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, fatty-liver disease, sleep apnea and other serious health conditions. Yet only a small percentage of eligible patients currently receives modern prescription weight-loss treatments. That gap explains why analysts believe the global weight-loss drug market could eventually exceed $100 billion in annual sales.
The Next Winners May Offer More Than Weight Loss
The next phase of the obesity drug boom will not be based solely on which treatment produces the highest percentage of weight loss. Drugmakers are now developing oral GLP-1 pills, monthly injections, dual- and triple-hormone therapies, amylin-based medicines and treatments designed to preserve muscle while patients lose fat.
Here is an important piece of trivia: weight loss does not come entirely from body fat. Patients may also lose lean tissue, including muscle, which has pushed biotechnology companies to develop complementary treatments that improve the quality of weight loss. Others are working on easier dosing, fewer gastrointestinal side effects and medicines that may also improve liver, heart and metabolic health.
Oral obesity treatments could become especially disruptive. Many patients dislike needles, while pills may be easier to manufacture, distribute and use. A successful weight-loss pill would not necessarily need to outperform every injectable treatment. Convenience alone could allow it to capture a meaningful portion of the growing obesity treatment market.
Why Biotech Stocks Are Entering the Spotlight
Novo Nordisk A/S (NYSE: NVO) remains the company framing this story, but it is not included in the top 10 ranking. Instead, the countdown focuses on biotechnology stocks attempting to benefit from the market Novo Nordisk helped create.
Some of these companies are developing direct competitors to existing GLP-1 drugs. Others are pursuing different mechanisms, longer-lasting treatments or therapies that could eventually be prescribed alongside popular weight-loss medicines. Their success could lead to major commercial partnerships, acquisition interest or sharp valuation increases.
The risks are equally significant. Obesity drug trials are expensive, clinical results can disappoint and smaller biotechnology companies may need additional financing before reaching commercialization. Investors searching for the best biotech stocks to buy now should therefore examine clinical progress, cash reserves, safety data, competitive advantages and upcoming catalysts—not just ambitious weight-loss claims.
The following countdown identifies 10 biotechnology stocks positioned to participate in the next stage of the $100 billion weight-loss drug market, beginning with number 10 and moving toward the company offering the strongest combination of scientific promise, market opportunity and investment potential.
CHECK THIS OUT: Top 10 AI-Powered Healthcare Stocks That Can Make You Rich and Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger.
Our Methodology
In order to arrive to our list of the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market, we examined the trending biotech stocks and based our ranking on each company’s clinical progress, treatment differentiation, market opportunity, financial position, upcoming catalysts, partnership potential and overall risk-reward profile within the rapidly growing obesity and metabolic-disease market.
10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market
9. Altimmune Inc. (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ: ALT) remains connected to the weight-loss revolution through pemvidutide, a dual GLP-1 and glucagon receptor agonist that previously generated encouraging weight-loss and body-composition data. However, the company has increasingly concentrated its development strategy on liver diseases, including metabolic dysfunction-associated steatohepatitis, alcohol-associated liver disease and alcohol-use disorder. That shift makes Altimmune, Inc. (NASDAQ: ALT) a less direct obesity play than some companies ranked above it, but it could also provide a differentiated route into the broader metabolic-disease market.
The scientific case centers on the balanced activation of GLP-1 and glucagon receptors. GLP-1 activity may reduce appetite and food intake, while glucagon activation could increase energy expenditure and help reduce liver fat. This combination is particularly relevant for people whose obesity is accompanied by fatty-liver disease, inflammation and metabolic dysfunction. The opportunity is not simply to help patients lose pounds; it is to determine whether the same medicine can improve the health of the liver while supporting favorable changes in body composition.
The major concern is that Altimmune, Inc. (NASDAQ: ALT) must compete against much larger companies with deeper financial resources, extensive commercial networks and late-stage metabolic pipelines. The stock’s depressed valuation reflects uncertainty surrounding development strategy, financing and pemvidutide’s eventual commercial positioning. Yet that lower valuation could also create considerable upside if future MASH studies confirm a meaningful benefit and management secures a credible pharmaceutical partner. Altimmune, Inc. (NASDAQ: ALT) belongs on the list because the obesity market is evolving beyond headline weight-loss percentages toward treatments that address the liver, cardiovascular system and other consequences of metabolic disease.
YOU MUST READ THIS: 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
